{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:27:18Z","timestamp":1788838038298,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T00:00:00Z","timestamp":1547424000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s00115-018-0666-2","type":"journal-article","created":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T15:17:52Z","timestamp":1547479072000},"page":"121-130","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Mitochondriale Erkrankungen","Mitochondrial diseases"],"prefix":"10.1007","volume":"90","author":[{"given":"Florentine","family":"Radelfahr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Klopstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,14]]},"reference":[{"key":"666_CR1","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/nm.3261","volume":"19","author":"SR Bacman","year":"2013","unstructured":"Bacman SR, Williams SL, Pinto M et al (2013) Specific elimination of mutant mitochondrial genomes in patient-derived cells by mitoTALENs. Nat Med 19:1111\u20131113","journal-title":"Nat Med"},{"key":"666_CR2","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/clpt.2010.55","volume":"88","author":"JP Bonnefont","year":"2010","unstructured":"Bonnefont JP, Bastin J, Laforet P et al (2010) Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency. Clin Pharmacol Ther 88:101\u2013108","journal-title":"Clin Pharmacol Ther"},{"key":"666_CR3","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/mus.880160205","volume":"16","author":"Y Campos","year":"1993","unstructured":"Campos Y, Huertas R, Lorenzo G et al (1993) Plasma carnitine insufficiency and effectiveness of L\u2011carnitine therapy in patients with mitochondrial myopathy. Muscle Nerve 16:150\u2013153","journal-title":"Muscle Nerve"},{"key":"666_CR4","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1080\/07853890510007368","volume":"37","author":"S Dimauro","year":"2005","unstructured":"Dimauro S, Davidzon G (2005) Mitochondrial DNA and disease. Ann Med 37:222\u2013232","journal-title":"Ann Med"},{"key":"666_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0076-6879(09)05001-0","volume":"457","author":"M Elstner","year":"2009","unstructured":"Elstner M, Andreoli C, Klopstock T et\u00a0al (2009) The mitochondrial proteome database: MitoP2. Meth Enzymol 457:3\u201320","journal-title":"Meth Enzymol"},{"key":"666_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ymgme.2011.10.009","volume":"105","author":"GM Enns","year":"2012","unstructured":"Enns GM, Kinsman SL, Perlman SL et al (2012) Initial experience in the treatment of inherited mitochondrial disease with EPI-743. Mol Genet Metab 105:91\u2013102","journal-title":"Mol Genet Metab"},{"key":"666_CR7","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.ophtha.2015.10.025","volume":"123","author":"WJ Feuer","year":"2016","unstructured":"Feuer WJ, Schiffman JC, Davis JL et\u00a0al (2016) Gene therapy for Leber hereditary optic neuropathy: initial results. Ophthalmology 123:558\u2013570","journal-title":"Ophthalmology"},{"key":"666_CR8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ymgme.2014.04.008","volume":"112","author":"T Fujii","year":"2014","unstructured":"Fujii T, Nozaki F, Saito K et al (2014) Efficacy of pyruvate therapy in patients with mitochondrial disease: a\u00a0semi-quantitative clinical evaluation study. Mol Genet Metab 112:133\u2013138","journal-title":"Mol Genet Metab"},{"key":"666_CR9","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/emmm.201303672","volume":"6","author":"PA Gammage","year":"2014","unstructured":"Gammage PA, Rorbach J, Vincent AI et al (2014) Mitochondrially targeted ZFNs for selective degradation of pathogenic mitochondrial genomes bearing large-scale deletions or point mutations. EMBO Mol Med 6:458\u2013466","journal-title":"EMBO Mol. Med."},{"key":"666_CR10","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1093\/brain\/awm054","volume":"130","author":"K Gempel","year":"2007","unstructured":"Gempel K, Topaloglu H, Talim B et al (2007) The myopathic form of coenzyme Q10 deficiency is caused by mutations in the electron-transferring-flavoprotein dehydrogenase (ETFDH) gene. Brain 130:2037\u20132044","journal-title":"Brain"},{"key":"666_CR11","volume-title":"GeneReviews","author":"M Hirano","year":"1993","unstructured":"Hirano M (1993) Mitochondrial neurogastrointestinal encephalopathy disease. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A (Hrsg) GeneReviews. University of Washington, Seattle"},{"key":"666_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1197","author":"MCH Janssen","year":"2018","unstructured":"Janssen MCH, Koene S, De Laat P et\u00a0al (2018) The KHENERGY study: safety and efficacy of KH176 in mitochondrial m.3243A\u3009G spectrum disorders. Clin Pharmacol Ther. \n                    https:\/\/doi.org\/10.1002\/cpt.1197","journal-title":"Clin Pharmacol Ther"},{"key":"666_CR13","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000005461","author":"A Karaa","year":"2018","unstructured":"Karaa A, Haas R, Goldstein A et al (2018) Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Baillieres Clin Neurol. \n                    https:\/\/doi.org\/10.1212\/wnl.0000000000005461","journal-title":"Baillieres Clin Neurol"},{"key":"666_CR14","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1093\/brain\/awp158","volume":"132","author":"MA Kirkman","year":"2009","unstructured":"Kirkman MA, Yu-Wai-Man P, Korsten A et al (2009) Gene-environment interactions in Leber hereditary optic neuropathy. Brain 132:2317\u20132326","journal-title":"Brain"},{"key":"666_CR15","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13073-016-0380-2","volume":"8","author":"T Klopstock","year":"2016","unstructured":"Klopstock T, Klopstock B, Prokisch H (2016) Mitochondrial replacement approaches: challenges for clinical implementation. Genome Med 8:126","journal-title":"Genome Med"},{"key":"666_CR16","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1093\/brain\/awr170","volume":"134","author":"T Klopstock","year":"2011","unstructured":"Klopstock T, Yu-Wai-Man P, Dimitriadis K et al (2011) A randomized placebo-controlled trial of idebenone in Leber\u2019s hereditary optic neuropathy. Brain 134:2677\u20132686","journal-title":"Brain"},{"key":"666_CR17","first-page":"1748","volume":"55","author":"T Klopstock","year":"2000","unstructured":"Klopstock T, Querner V, Schmidt F et al (2000) A placebo-controlled crossover trial of creatine in mitochondrial diseases. Neurology 55:1748-1751","journal-title":"Baillieres Clin Neurol"},{"key":"666_CR18","first-page":"275\u202fff","volume-title":"Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie","author":"C Kornblum","year":"2017","unstructured":"Kornblum C, Klopstock T (2017) Mitochondriale Erkrankungen. In: Diener HC, Weimar C (Hrsg) Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. Thieme, Stuttgart, S\u00a0275\u202fff"},{"key":"666_CR19","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/j.1468-1331.2004.00970.x","volume":"12","author":"C Kornblum","year":"2005","unstructured":"Kornblum C, Schroder R, Muller K et al (2005) Creatine has no beneficial effect on skeletal muscle energy metabolism in patients with single mitochondrial DNA deletions: a\u00a0placebo-controlled, double-blind 31P-MRS crossover study. Eur J Neurol 12:300\u2013309","journal-title":"Eur J Neurol"},{"key":"666_CR20","first-page":"1461","volume":"67","author":"MC Lara","year":"2006","unstructured":"Lara MC, Weiss B, Illa I et\u00a0al (2006) Infusion of platelets transiently reduces nucleoside overload in MNGIE. Baillieres Clin Neurol 67:1461\u20131463","journal-title":"Baillieres Clin Neurol"},{"key":"666_CR21","first-page":"884","volume":"43","author":"PM Matthews","year":"1993","unstructured":"Matthews PM, Ford B, Dandurand RJ et\u00a0al (1993) Coenzyme Q10 with multiple vitamins is generally ineffective in treatment of mitochondrial disease. Baillieres Clin Neurol 43:884\u2013890","journal-title":"Baillieres Clin Neurol"},{"key":"666_CR22","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/BF02002711","volume":"155","author":"A Munnich","year":"1996","unstructured":"Munnich A, Rotig A, Chretien D et\u00a0al (1996) Clinical presentations and laboratory investigations in respiratory chain deficiency. Eur J Pediatr 155:262\u2013274","journal-title":"Eur J Pediatr"},{"key":"666_CR23","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1093\/brain\/awn252","volume":"131","author":"JL Murphy","year":"2008","unstructured":"Murphy JL, Blakely EL, Schaefer AM et al (2008) Resistance training in patients with single, large-scale deletions of mitochondrial DNA. Brain 131:2832\u20132840","journal-title":"Brain"},{"key":"666_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-317964","author":"Y Ohsawa","year":"2018","unstructured":"Ohsawa Y, Hagiwara H, Nishimatsu SI et al (2018) Taurine supplementation for prevention of stroke-like episodes in MELAS: a\u00a0multicentre, open-label, 52-week phase III trial. J\u00a0Neurol Neurosurg Psychiatry. \n                    https:\/\/doi.org\/10.1136\/jnnp-2018-317964","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"666_CR25","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s10545-014-9779-3","volume":"38","author":"MC Orngreen","year":"2015","unstructured":"Orngreen MC, Vissing J, Laforet P (2015) No effect of bezafibrate in patients with CPTII and VLCAD deficiencies. J\u00a0Inherit Metab Dis 38:373\u2013374","journal-title":"J Inherit Metab Dis"},{"key":"666_CR26","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/gim.2014.177","volume":"17","author":"S Parikh","year":"2015","unstructured":"Parikh S, Goldstein A, Koenig MK et\u00a0al (2015) Diagnosis and management of mitochondrial disease: a\u00a0consensus statement from the Mitochondrial Medicine Society. Genet Med 17:689\u2013701","journal-title":"Genet Med"},{"key":"666_CR27","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1055\/a-0621-9255","volume":"86","author":"F Radelfahr","year":"2018","unstructured":"Radelfahr F, Klopstock T (2018) Diagnostic and therapeutic approaches for mitochondrial diseases. Fortschr Neurol Psychiatr 86:584\u2013591","journal-title":"Fortschr Neurol Psychiatr"},{"key":"666_CR28","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1042\/EBC20170113","volume":"62","author":"PK Rai","year":"2018","unstructured":"Rai PK, Craven L, Hoogewijs K et\u00a0al (2018) Advances in methods for reducing mitochondrial DNA disease by replacing or manipulating the mitochondrial genome. Essays Biochem 62:455\u2013465","journal-title":"Essays Biochem"},{"key":"666_CR29","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13023-018-0784-8","volume":"13","author":"BM Repp","year":"2018","unstructured":"Repp BM, Mastantuono E, Alston CL et\u00a0al (2018) Clinical, biochemical and genetic spectrum of 70 patients with ACAD9 deficiency: is riboflavin supplementation effective? Orphanet J Rare Dis 13:120","journal-title":"Orphanet J Rare Dis"},{"key":"666_CR30","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.scr.2016.09.007","volume":"24","author":"D Romero-Moya","year":"2017","unstructured":"Romero-Moya D, Castano J, Santos-Ocana C et al (2017) Generation, genome edition and characterization of iPSC lines from a\u00a0patient with coenzyme Q10 deficiency harboring a\u00a0heterozygous mutation in COQ4 gene. Stem Cell Res 24:144\u2013147","journal-title":"Stem Cell Res"},{"key":"666_CR31","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/WNO.0b013e318272c643","volume":"33","author":"G Rudolph","year":"2013","unstructured":"Rudolph G, Dimitriadis K, Buchner B et\u00a0al (2013) Effects of idebenone on color vision in patients with leber hereditary optic neuropathy. J\u00a0Neuroophthalmol 33:30\u201336","journal-title":"J Neuroophthalmol"},{"key":"666_CR32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/ana.21217","volume":"63","author":"AM Schaefer","year":"2008","unstructured":"Schaefer AM, Mcfarland R, Blakely EL et\u00a0al (2008) Prevalence of mitochondrial DNA disease in adults. Ann Neurol 63:35\u201339","journal-title":"Ann Neurol"},{"key":"666_CR33","doi-asserted-by":"publisher","first-page":"552","DOI":"10.3389\/fneur.2018.00552","volume":"9","author":"KS Seo","year":"2018","unstructured":"Seo KS, Kim JH, Min KN et\u00a0al (2018) KL1333, a\u00a0novel NAD(+) modulator, improves energy metabolism and mitochondrial dysfunction in MELAS fibroblasts. Front Neurol 9:552","journal-title":"Front Neurol"},{"key":"666_CR34","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s15005-016-1783-8","volume":"18","author":"C Stendel","year":"2016","unstructured":"Stendel C, Klopstock T (2016) Mitochondriale Erkrankungen. InFo Neurol 18:36\u201348","journal-title":"InFo Neurol"},{"key":"666_CR35","doi-asserted-by":"publisher","first-page":"21587","DOI":"10.1038\/srep21587","volume":"6","author":"X Wan","year":"2016","unstructured":"Wan X, Pei H, Zhao MJ et al (2016) Efficacy and safety of rAAV2-ND4 treatment for Leber\u2019s hereditary optic neuropathy. Sci Rep 6:21587","journal-title":"Sci Rep"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-018-0666-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-018-0666-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-018-0666-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,14]],"date-time":"2020-01-14T00:26:13Z","timestamp":1578961573000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-018-0666-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,14]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["666"],"URL":"https:\/\/doi.org\/10.1007\/s00115-018-0666-2","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,14]]},"assertion":[{"value":"14 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Die Autoren erkl\u00e4ren, dass sie sich bei der Erstellung des Beitrags von keinen wirtschaftlichen Interessen haben leiten lassen. T.\u00a0Klopstock gibt an, dass er Forschungsgelder, Reisekosten, Vortrags- und Beratungshonorare von den Firmen Santhera Pharmaceuticals und GenSight Biologics erhalten hat, deren Produkte im Artikel direkt oder indirekt genannt werden. F.\u00a0Radelfahr gibt keine Interessenkonflikte an.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}